# Neuromodtronic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuromodtronic

- Industry: Healthcare Specialists
- Headquarters: Potsdam, Germany
- Website: www.eyetronic-therapie.de
- Total disclosed funding: $4.5M
- Latest round: Series B (Dec 16, 2009)
- Investors on record: 4

## About

Neuromodtronic GmbH specializes in innovative non-invasive therapies aimed at restoring vision for patients with visual field loss, particularly due to glaucoma and optic nerve disorders.Founded in 2007 and headquartered in Potsdam, Germany, Neuromodtronic GmbH focuses on advancing therapies for visual impairments. The company has raised EUR 1.10 mn in its latest GROWTH funding round as of June 1, 2017, led by Earlybird Venture Capital and High-Tech Gruenderfonds, bringing the total amount raised to EUR 1.10 mn. The founder, Christian Schultz, has a history in the medical technology field, although no details about prior companies are available.Eyetronic specializes in a non-invasive therapy designed to restore vision for patients experiencing visual field loss due to glaucoma and other optic nerve disorders. The core offering is the Eyetronic Therapy, which leverages targeted alternating current tailored to individual patients to stimulate the metabolism of surviving retinal nerve cells. This therapy aims to enhance cellular function and prevent further deterioration of vision. Eyetronic Therapy has been clinically validated through studies and has been available since 2014 at select medical centers. The company primarily serves patients in Germany and other European markets who are seeking alternatives to traditional treatments for vision loss, catering to a clientele that includes healthcare providers and eye care specialists.Eyetronic's revenue model is primarily structured around partnerships with medical centers and clinics that offer the Eyetronic Therapy to patients. These clinics purchase the Eyetronic system and incorporate it into their treatment offerings for patients suffering from visual impairments. The company generates income through direct sales of its CE-certified Eyetronic systems, along with potential service agreements for ongoing support and maintenance. Additionally, the therapy may be included in treatment plans, indicating a structured payment model where healthcare providers bill patients directly or work with insurance companies for reimbursement. This focus on a specialized medical device and therapy creates a niche market for Eyetronic, targeting both B2B relationships with healthcare providers and direct interactions with end-users receiving treatment.In June 2017, Neuromodtronic GmbH raised EUR 3 mn in venture debt funding from Hayfin Capital Management. The company will use the funding to accelerate its growth, expand its commercial presence in EU countries, and support a clinical trial in the US. Neuromodtronic plans to develop new products in its therapy line to enhance treatment options and is exploring opportunities to enter additional European and North American markets by 2025.

## Funding rounds

- Series B, Dec 16, 2009, $4.5M — Earlybird, High-Tech Gruenderfonds, Brandenburg Kapital
- Seed, Mar 1, 2009 — High-Tech Gruenderfonds, InvestitionsBank des Landes Brandenburg

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series B
- InvestitionsBank des Landes Brandenburg — Seed
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series B
- Brandenburg Kapital (https://capitalatlas.ai/funds/brandenburg-kapital) — Series B